1-3 of 3
Sharon T. Sullivan, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy

Nina Wagner-Johnston, MD, Andre Goy, MD, Maria Alma Rodriguez, MD, Christopher Ehmann, MD, Paul Hamlin, MD, John Radford, MD, Catherine Thieblemont, MD, Cheolwon Suh, MD, John Sweetenham, MD, Ying Jiang, PhD, Sharon T Sullivan, PhD, Erik R Vandendries, MD, PhD, Christian Gisselbrecht, MD
Journal: Blood
Blood (2011) 118 (21): 2718.
https://doi.org/10.1182/blood.V118.21.2718.2718
Published: 2011
Journal Articles

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab In Relapsed DLBCL Patients Followed by Stem Cell Transplantation: Preliminary Safety and Efficacy

Nina Wagner-Johnston, Andre Goy, MD, Tatyana Feldman, MD, Yeow Tee Goh, MD, Cheolwon Suh, MD, John William Sweetenham, MD, FRCP, Christine Powell, Sharon T. Sullivan, PhD, Erik R. Vandendries, MD, PhD, Christian Gisselbrecht, MD
Journal: Blood
Blood (2010) 116 (21): 2883.
https://doi.org/10.1182/blood.V116.21.2883.2883
Published: 2010
Journal Articles

A New Formulation of Recombinant Human Factor IX Is Bioequivalent to BeneFIX: A Double-Blind, Randomized, Crossover Pharmacokinetic and Open-Label Safety and Efficacy Study.

Jerry Sherman Powell, MD, Thierry Lambert, MD, F. Hernández Navarro, MD, Michael Recht, MD, Sharon T. Sullivan, PhD, Chandrasekhar Udata, PhD, Leslie C. Lilly, BSN, RN, David A. Roth, MD, The rFIX-R Study Group
Journal: Blood
Blood (2005) 106 (11): 4076.
https://doi.org/10.1182/blood.V106.11.4076.4076
Published: 2005